Summary:
IdentifAI has developed a NIPT technology that detects 250 hereditary genetic disorders.
Technology isolates fetal DNA and uses AI for genetic sequencing as early as nine weeks.
Clinical trials show accuracy matching that of amniocentesis.
The NIPT market is expected to grow from $6 billion to $19 billion by 2030.
IdentifAI has raised $6.5 million in funding and employs 15 people in Tel Aviv.
IdentifAI's Groundbreaking Prenatal Testing
IdentifAI, an Israeli health-tech company, has developed a non-invasive prenatal testing (NIPT) technology that can identify 250 hereditary genetic disorders from a maternal blood sample. This innovative solution builds on the research of Professor Noam Shomron, a prominent expert in genetics and bioinformatics at Tel Aviv University.
Advanced DNA Analysis
The company's approach involves isolating fetal DNA from maternal DNA in blood samples, utilizing artificial intelligence and machine learning to conduct full genetic sequencing as early as nine weeks into pregnancy. This represents a significant advancement over current NIPT capabilities, which typically only detect around 25 genetic conditions like Tay-Sachs and cystic fibrosis.
Proven Accuracy in Clinical Trials
Clinical trials at Beilinson and Meir hospitals in Israel have demonstrated the technology's accuracy. In tests involving 18 pregnant women, IdentifAI’s system accurately identified fetal risks, matching results with amniocentesis, a more invasive procedure. These findings were published in Prenatal Diagnosis, a leading journal in the field.
Expanding Trials in the U.S.
IdentifAI is currently conducting further trials in the United States, including a recent study at Columbia University Medical Center. Seven additional U.S. medical centers are set to participate in upcoming trials.
Addressing Limitations of Traditional Testing
While traditional amniocentesis is considered the gold standard for prenatal genetic testing, its invasive nature poses risks to both mother and fetus. NIPTs have gained popularity as safer alternatives but have been limited in their scope. IdentifAI’s technology, which can detect mutations in single DNA bases, aims to fill this gap.
Growing Market Potential
The NIPT market is projected to grow significantly, from its current $6 billion valuation to $19 billion by 2030, fueled by advancements in technology and rising demand for non-invasive solutions.
Funding and Growth
To date, IdentifAI has raised $6.5 million from eHealth Ventures, Shizim Fund, and other investors, alongside grants from the Israel Innovation Authority. The company currently employs 15 people in its Tel Aviv offices.
Comments